Latest Pharma Insights
McKinsey Execs On Perfecting The US Launch Recipe, Do’s For First-Time Launchers
Senior McKinsey executives discuss how biopharma can ace its US launch strategy and first-time launchers can stack the odds in their favor amid complex market dynamics including the MFN pricing push.
Scrip - November 6, 2025
Senior McKinsey executives discuss how biopharma can ace its US launch strategy and first-time launchers can stack the odds in their favor amid complex market dynamics including the MFN pricing push.
Scrip - November 6, 2025
Perrigo Eyes Big Decision On Formula Business Three Years After Going Big With Expansion
Perrigo pauses $240m spending planned for formula business as it considers options to be in better position to boost growth on OTC drugs. “Problems make formula manufacturing’s “long-term fit alongside our faster-growing, higher-cash-yielding consumer health OTC portfolio less strategic,” says presi
HBW Insight - November 6, 2025
Perrigo pauses $240m spending planned for formula business as it considers options to be in better position to boost growth on OTC drugs. “Problems make formula manufacturing’s “long-term fit alongside our faster-growing, higher-cash-yielding consumer health OTC portfolio less strategic,” says presi
HBW Insight - November 6, 2025
Smaller Companies Next Frontier for FDA’s Voluntary Improvement Program
At the Medical Device Innovation Consortium summit, Cogmedix's Scott Cook discussed the challenges and benefits of transitioning to the FDA's Voluntary Improvement Program, which promotes honesty and opportunities for improvement, leading to faster market access and cost savings.
Medtech Insight - November 6, 2025
At the Medical Device Innovation Consortium summit, Cogmedix's Scott Cook discussed the challenges and benefits of transitioning to the FDA's Voluntary Improvement Program, which promotes honesty and opportunities for improvement, leading to faster market access and cost savings.
Medtech Insight - November 6, 2025
McKinsey Execs On Perfecting The US Launch Recipe, Do’s For First-Time Launchers
Senior McKinsey executives discuss how biopharma can ace its US launch strategy and first-time launchers can stack the odds in their favor amid complex market dynamics including the MFN pricing push.
Scrip - November 6, 2025
Senior McKinsey executives discuss how biopharma can ace its US launch strategy and first-time launchers can stack the odds in their favor amid complex market dynamics including the MFN pricing push.
Scrip - November 6, 2025
Smaller Companies Next Frontier for FDA’s Voluntary Improvement Program
At the Medical Device Innovation Consortium summit, Cogmedix's Scott Cook discussed the challenges and benefits of transitioning to the FDA's Voluntary Improvement Program, which promotes honesty and opportunities for improvement, leading to faster market access and cost savings.
Medtech Insight - November 6, 2025
At the Medical Device Innovation Consortium summit, Cogmedix's Scott Cook discussed the challenges and benefits of transitioning to the FDA's Voluntary Improvement Program, which promotes honesty and opportunities for improvement, leading to faster market access and cost savings.
Medtech Insight - November 6, 2025
Perrigo Eyes Big Decision On Formula Business Three Years After Going Big With Expansion
Perrigo pauses $240m spending planned for formula business as it considers options to be in better position to boost growth on OTC drugs. “Problems make formula manufacturing’s “long-term fit alongside our faster-growing, higher-cash-yielding consumer health OTC portfolio less strategic,” says presi
HBW Insight - November 6, 2025
Perrigo pauses $240m spending planned for formula business as it considers options to be in better position to boost growth on OTC drugs. “Problems make formula manufacturing’s “long-term fit alongside our faster-growing, higher-cash-yielding consumer health OTC portfolio less strategic,” says presi
HBW Insight - November 6, 2025
Outgoing Cipla CEO On Key Wins, Unfinished Agenda, Biosimilars ‘Explosion’ To Come
Cipla’s global CEO and MD Umang Vohra is moving on handing over the baton to global COO, Achin Gupta. Vohra talks about his innings, where he sees Cipla in 2030 and the impact of the latest FDA action that aims to make biosimilar development faster and less costly.
Generics Bulletin - November 5, 2025
Cipla’s global CEO and MD Umang Vohra is moving on handing over the baton to global COO, Achin Gupta. Vohra talks about his innings, where he sees Cipla in 2030 and the impact of the latest FDA action that aims to make biosimilar development faster and less costly.
Generics Bulletin - November 5, 2025
Biogen Fights To Defend MS Franchise Amid Generic Erosion And Biosimilar Threats
On its third-quarter earnings call, Biogen’s management said the company remains well positioned despite accelerating generic pressure in Europe and the imminent US launch of Sandoz’s Tyruko biosimilar.
Generics Bulletin - November 5, 2025
On its third-quarter earnings call, Biogen’s management said the company remains well positioned despite accelerating generic pressure in Europe and the imminent US launch of Sandoz’s Tyruko biosimilar.
Generics Bulletin - November 5, 2025
Amgen Warns Against Turning Biosimilars Into Generics
With the FDA moving to ease biosimilar approval requirements, Amgen’s leadership urged Washington to preserve the high regulatory bar that has favored experienced biologics manufacturers.
Generics Bulletin - November 5, 2025
With the FDA moving to ease biosimilar approval requirements, Amgen’s leadership urged Washington to preserve the high regulatory bar that has favored experienced biologics manufacturers.
Generics Bulletin - November 5, 2025
ResMed Taps Wearables And GLP-1 Trends To Expand Sleep Care
Resmed’s CMO Carlos Nunez discusses the sleep giant’s continued push from medtech into healthtech and its efforts to fix what he calls a “broken pathway” to diagnosis and treatment for millions with undetected sleep apnea.
In Vivo - November 5, 2025
Resmed’s CMO Carlos Nunez discusses the sleep giant’s continued push from medtech into healthtech and its efforts to fix what he calls a “broken pathway” to diagnosis and treatment for millions with undetected sleep apnea.
In Vivo - November 5, 2025
How Abdul Mullick Is Leading Kyowa Kirin’s Global Transformation
The Japanese pharma specialist has embarked on an ambitious journey to become a global specialty pharmaceutical company, driven by its first non-Japanese president at the helm.
In Vivo - November 5, 2025
The Japanese pharma specialist has embarked on an ambitious journey to become a global specialty pharmaceutical company, driven by its first non-Japanese president at the helm.
In Vivo - November 5, 2025